These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 38111057)
1. Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration. Zhao B; Cowan CM; Coutts JA; Christy DD; Saraph A; Hsueh SCC; Plotkin SS; Mackenzie IR; Kaplan JM; Cashman NR Acta Neuropathol Commun; 2023 Dec; 11(1):200. PubMed ID: 38111057 [TBL] [Abstract][Full Text] [Related]
2. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. Igaz LM; Kwong LK; Lee EB; Chen-Plotkin A; Swanson E; Unger T; Malunda J; Xu Y; Winton MJ; Trojanowski JQ; Lee VM J Clin Invest; 2011 Feb; 121(2):726-38. PubMed ID: 21206091 [TBL] [Abstract][Full Text] [Related]
3. Increased cytoplasmic TDP-43 reduces global protein synthesis by interacting with RACK1 on polyribosomes. Russo A; Scardigli R; La Regina F; Murray ME; Romano N; Dickson DW; Wolozin B; Cattaneo A; Ceci M Hum Mol Genet; 2017 Apr; 26(8):1407-1418. PubMed ID: 28158562 [TBL] [Abstract][Full Text] [Related]
4. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS. Ito D; Suzuki N Neurology; 2011 Oct; 77(17):1636-43. PubMed ID: 21956718 [TBL] [Abstract][Full Text] [Related]
6. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43). Bentmann E; Neumann M; Tahirovic S; Rodde R; Dormann D; Haass C J Biol Chem; 2012 Jun; 287(27):23079-94. PubMed ID: 22563080 [TBL] [Abstract][Full Text] [Related]
7. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients. Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125 [TBL] [Abstract][Full Text] [Related]
8. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins. Ratti A; Buratti E J Neurochem; 2016 Aug; 138 Suppl 1():95-111. PubMed ID: 27015757 [TBL] [Abstract][Full Text] [Related]
9. How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other? Baloh RH Curr Opin Neurol; 2012 Dec; 25(6):701-7. PubMed ID: 23041957 [TBL] [Abstract][Full Text] [Related]
10. Mislocated FUS is sufficient for gain-of-toxic-function amyotrophic lateral sclerosis phenotypes in mice. Shiihashi G; Ito D; Yagi T; Nihei Y; Ebine T; Suzuki N Brain; 2016 Sep; 139(Pt 9):2380-94. PubMed ID: 27368346 [TBL] [Abstract][Full Text] [Related]
11. Stress granules in neurodegeneration--lessons learnt from TAR DNA binding protein of 43 kDa and fused in sarcoma. Bentmann E; Haass C; Dormann D FEBS J; 2013 Sep; 280(18):4348-70. PubMed ID: 23587065 [TBL] [Abstract][Full Text] [Related]
12. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. Sun Z; Diaz Z; Fang X; Hart MP; Chesi A; Shorter J; Gitler AD PLoS Biol; 2011 Apr; 9(4):e1000614. PubMed ID: 21541367 [TBL] [Abstract][Full Text] [Related]
13. Human TDP-43 and FUS selectively affect motor neuron maturation and survival in a murine cell model of ALS by non-cell-autonomous mechanisms. Wächter N; Storch A; Hermann A Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(7-8):431-41. PubMed ID: 26174443 [TBL] [Abstract][Full Text] [Related]
14. Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. Bigio EH; Wu JY; Deng HX; Bit-Ivan EN; Mao Q; Ganti R; Peterson M; Siddique N; Geula C; Siddique T; Mesulam M Acta Neuropathol; 2013 Mar; 125(3):463-5. PubMed ID: 23378033 [No Abstract] [Full Text] [Related]
15. Atypical FTLD-FUS associated with ALS-TDP: a case report. Kobayashi Z; Arai T; Yokota O; Tsuchiya K; Hosokawa M; Oshima K; Niizato K; Akiyama H; Mizusawa H Neuropathology; 2013 Feb; 33(1):83-6. PubMed ID: 22640227 [TBL] [Abstract][Full Text] [Related]
16. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723 [TBL] [Abstract][Full Text] [Related]
17. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Walker AK; Spiller KJ; Ge G; Zheng A; Xu Y; Zhou M; Tripathy K; Kwong LK; Trojanowski JQ; Lee VM Acta Neuropathol; 2015 Nov; 130(5):643-60. PubMed ID: 26197969 [TBL] [Abstract][Full Text] [Related]
18. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. Riku Y; Iwasaki Y; Ishigaki S; Akagi A; Hasegawa M; Nishioka K; Li Y; Riku M; Ikeuchi T; Fujioka Y; Miyahara H; Sone J; Hattori N; Yoshida M; Katsuno M; Sobue G Brain; 2022 Aug; 145(8):2769-2784. PubMed ID: 35274674 [TBL] [Abstract][Full Text] [Related]
19. Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice. Shelkovnikova TA; Peters OM; Deykin AV; Connor-Robson N; Robinson H; Ustyugov AA; Bachurin SO; Ermolkevich TG; Goldman IL; Sadchikova ER; Kovrazhkina EA; Skvortsova VI; Ling SC; Da Cruz S; Parone PA; Buchman VL; Ninkina NN J Biol Chem; 2013 Aug; 288(35):25266-25274. PubMed ID: 23867462 [TBL] [Abstract][Full Text] [Related]
20. TDP-43 and FUS/TLS: cellular functions and implications for neurodegeneration. Fiesel FC; Kahle PJ FEBS J; 2011 Oct; 278(19):3550-68. PubMed ID: 21777389 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]